Diagnostic Criteria and Management of Diabetic Ketoacidosis (DKA)

Core Diagnostic Parameters

The American Diabetes Association recommends that the diagnostic criteria for diabetic ketoacidosis (DKA) include blood glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and moderate ketonuria or ketonemia 1, 2
Hyperglycemia, defined as blood glucose >250 mg/dL, is a fundamental component of classic DKA diagnosis 1, 2
Acidosis, as indicated by venous pH <7.3, is required for diagnosis and reflects the severity of ketoacidosis 1
Low bicarbonate, defined as serum bicarbonate <15 mEq/L, indicates metabolic acidosis 1, 2
The presence of ketones, either moderate ketonuria or ketonemia, is a necessary criterion for DKA diagnosis 1, 2

Laboratory Evaluation

The American Diabetes Association suggests obtaining a complete metabolic panel, venous blood gases, complete blood count, urinalysis, and serum ketones immediately upon presentation 1, 3
Calculating the anion gap using the formula [Na⁺] - ([Cl⁻] + [HCO₃⁻]) helps assess the severity of metabolic acidosis 1
Correcting serum sodium for hyperglycemia using the formula [measured Na (mEq/L)] + [glucose (mg/dL) - 100]/100 × 1.6 is recommended 1, 4
Direct measurement of β-hydroxybutyrate (β-OHB) in blood is preferred over the nitroprusside method for diagnosing and monitoring DKA 5

Severity Classification

Mild DKA is characterized by a venous pH of 7.25-7.30, bicarbonate levels of 15-18 mEq/L, and alert mental status 3
Moderate DKA is defined by a venous pH of 7.00-7.24, bicarbonate levels of 10-15 mEq/L, and drowsy mental status 3

Monitoring During Treatment

Blood should be drawn every 2-4 hours to measure electrolytes, glucose, BUN, creatinine, osmolality, and venous pH during treatment 5
Venous pH and anion gap can be followed to monitor the resolution of acidosis 5
Ketonemia typically takes longer to clear than hyperglycemia, requiring continued monitoring 5

Resolution Criteria

Glucose levels <200 mg/dL indicate resolution of hyperglycemia 5
Serum bicarbonate ≥18 mEq/L and venous pH >7.3 are criteria for resolving metabolic acidosis 5
Anion gap ≤12 mEq/L also indicates resolution of acidosis 5

Common Pitfalls to Avoid

Relying solely on urine ketones for diagnosis or monitoring response to treatment is not recommended, as the nitroprusside method doesn't measure β-OHB 5
Discontinuing insulin therapy prematurely before ketoacidosis resolves can lead to recurrence 6
Inadequate monitoring of electrolytes, particularly potassium, during treatment can lead to complications 6

Diabetic Ketoacidosis Severity and Management

Diagnostic Parameters and Severity

Severe DKA is associated with higher morbidity and mortality, and often requires more intensive monitoring, including central venous and intra-arterial pressure monitoring, with a venous pH of <7.00 and serum bicarbonate of <10 mEq/L 7
The American Diabetes Association, as published in Diabetes Care, defines severe DKA as having a venous pH of <7.00 and serum bicarbonate of <10 mEq/L, which is associated with a higher risk of complications and mortality 7

Diagnostic Criteria and Initial Management for Diabetic Ketoacidosis (DKA)

Initial Laboratory Evaluation

Obtain bacterial cultures of urine, blood, and throat if infection is suspected, as recommended by the American Diabetes Association, to identify potential precipitating factors 8

Initial Management

Fluid Therapy

Begin aggressive fluid resuscitation with isotonic saline at 15-20 mL/kg/hour to restore circulatory volume and tissue perfusion, according to the American Diabetes Association guidelines 8
Subsequent fluid choice depends on hydration state, serum electrolytes, and urine output, as suggested by the American Diabetes Association 8

Electrolyte Management

Once renal function is assured, include 20-30 mEq/L potassium in IV fluids until patient can tolerate oral supplementation, as recommended by the American Diabetes Association 8

Diabetic Ketoacidosis Management

Fluid Resuscitation

The American Diabetes Association recommends beginning fluid resuscitation with isotonic saline at 15-20 mL/kg/hour, with subsequent fluid choice depending on hydration state, serum electrolytes, and urinary output 9, 10
Total fluid replacement should correct estimated deficits within 24 hours, with monitoring for fluid overload in patients with renal or cardiac compromise 9, 10

Insulin Therapy

The American Diabetes Association suggests adding dextrose to IV fluids to prevent hypoglycemia when blood glucose falls below 200-250 mg/dL, while continuing insulin infusion to clear ketones 9
Transition to subcutaneous insulin by administering basal insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia 11

Electrolyte Management

Include 20-30 mEq/L potassium in IV fluids once renal function is assured and serum potassium is known, with guidelines for potassium replacement based on serum potassium levels 9, 10

Special Considerations

The American Diabetes Association recommends against bicarbonate therapy for DKA management, except in cases where pH <6.9, and considers subcutaneous rapid-acting insulin as an alternative to IV insulin for mild to moderate DKA 11
Failing to identify and treat the underlying precipitating cause of DKA can lead to recurrence, according to the American Diabetes Association 11

Transition to Subcutaneous Insulin and Discharge Planning

Provide education on recognition, prevention, and management of DKA to prevent recurrence, as recommended by the American Diabetes Association 12

Arterial Blood Gas Parameters for DKA Evaluation

Essential Initial ABG Parameters

The American Diabetes Association recommends that for initial DKA assessment, arterial pH must be <7.3 for DKA diagnosis, with mild DKA: 7.25-7.30, moderate: 7.00-7.24, and severe: <7.00 13
The American Diabetes Association suggests evaluating PaO2 to assess oxygenation status and identify concurrent respiratory pathology 14

Critical Companion Laboratory Values

The American Diabetes Association recommends that serum bicarbonate should be <18 mEq/L for DKA diagnosis, with mild: 15-18, moderate: 10-15, and severe: <10 mEq/L 13
The American Diabetes Association suggests calculating the anion gap as [Na+] - ([Cl-] + [HCO3-]), which should be >10-12 mEq/L in DKA 13

Monitoring Strategy During Treatment

The American Diabetes Association recommends that after initial diagnosis, repeat arterial blood gases are generally unnecessary, and venous pH and anion gap adequately monitor acidosis resolution, with venous pH typically 0.03 units lower than arterial 15, 14

Common Pitfalls to Avoid

The American Diabetes Association advises against relying on urine ketones or nitroprusside methods, as they only measure acetoacetate and acetone, not β-OHB, and can falsely suggest worsening ketosis during treatment 15, 14
The American Diabetes Association recommends against repeating arterial sticks unnecessarily, as venous pH suffices for monitoring after initial diagnosis 15, 14

Monitoring Frequency for Beta-Hydroxybutyrate in Diabetic Ketoacidosis

Initial Assessment

The American Diabetes Association recommends obtaining beta-hydroxybutyrate measurement immediately as part of the initial diagnostic workup, along with blood glucose, venous blood gases, electrolytes, BUN, creatinine, and anion gap, when DKA is suspected 16.
Direct blood measurement of β-hydroxybutyrate is the preferred method for both diagnosis and monitoring of DKA, not the nitroprusside-based urine or serum tests, as recommended by the American Diabetes Association 16, 17, 18.

During Active DKA Treatment

The American Diabetes Association recommends monitoring beta-hydroxybutyrate every 2-4 hours during the treatment phase, checking alongside glucose, electrolytes, BUN, creatinine, osmolality, and venous pH 16, 19, 17.
This frequency allows tracking the resolution of ketosis, which typically takes longer to clear than hyperglycemia, according to the American Diabetes Association 16, 17.
Venous pH and anion gap can be followed in parallel to monitor acidosis resolution without requiring repeated arterial blood gases, as recommended by the American Diabetes Association 16, 19.

Critical Monitoring Pitfall to Avoid

The American Diabetes Association advises against using nitroprusside-based ketone tests (urine or serum) to monitor DKA treatment response, as they only measure acetoacetic acid and acetone, completely missing β-hydroxybutyrate—the predominant and strongest ketoacid in DKA 16, 19, 18.
During treatment, β-hydroxybutyrate is converted to acetoacetate, which paradoxically makes nitroprusside tests appear worse even as the patient improves, according to the American Diabetes Association 16, 17.

Resolution Criteria

DKA is considered resolved when all of the following are met: glucose <200 mg/dL 17, and venous pH >7.3 17, as recommended by the American Diabetes Association.
Continue monitoring beta-hydroxybutyrate until it normalizes (<0.5 mmol/L), even after urine ketones clear, as persistent elevations can lead to recurrent ketonuria if treatment is stopped prematurely, although the specific guideline is not provided.

Outpatient Monitoring Context

For patients at risk of ketosis (type 1 diabetes, history of DKA, or on SGLT2 inhibitors), beta-hydroxybutyrate should be checked whenever they experience unexplained hyperglycemia or symptoms of ketosis, as recommended by the American Diabetes Association 18, 20.
Blood β-hydroxybutyrate testing is superior to urine ketone testing for early detection of ketosis in the outpatient setting, allowing for earlier intervention with sick-day rules and preventing progression to full DKA, according to the American Diabetes Association 18, 20.

Diabetic Ketoacidosis Management

Fluid Resuscitation and Insulin Therapy

The American Diabetes Association recommends correcting serum sodium for hyperglycemia by adding 1.6 mEq/L for every 100 mg/dL glucose above 100, and starting continuous IV regular insulin infusion at 0.1 units/kg/hour without an initial bolus, in patients with diabetic ketoacidosis 21
The American Diabetes Association suggests that if glucose does not fall by 50 mg/dL in the first hour, the insulin infusion rate should be doubled hourly until a steady decline of 50-75 mg/dL per hour is achieved, in patients with diabetic ketoacidosis 21

Potassium Replacement

The American Diabetes Association recommends adding 20-30 mEq potassium per liter of IV fluid to maintain serum potassium 4-5 mEq/L, once serum potassium falls below 5.5 mEq/L and adequate urine output is confirmed, in patients with diabetic ketoacidosis 22, 21
The American Diabetes Association advises delaying insulin therapy and aggressively replacing potassium first if initial potassium is <3.3 mEq/L, to prevent fatal cardiac arrhythmias in patients with diabetic ketoacidosis 22, 21

Special Considerations

The American Diabetes Association suggests monitoring closely for cerebral edema during treatment, especially with overly aggressive fluid resuscitation, in patients with diabetic ketoacidosis 22, 21

Management of Diabetic Ketoacidosis

Immediate Initial Management

The American Diabetes Association recommends starting continuous IV regular insulin infusion at 0.1 units/kg/hour without a bolus dose for patients with diabetic ketoacidosis and altered mental status 23
Aggressive fluid resuscitation with isotonic (0.9%) saline at 15-20 mL/kg/hour should be initiated to restore circulatory volume and tissue perfusion in patients with diabetic ketoacidosis 24

Critical Management Considerations

For unconscious patients with diabetic ketoacidosis, continuous IV insulin is necessary, and subcutaneous insulin is not appropriate 24
The American Diabetes Association recommends administering basal subcutaneous insulin 2-4 hours before stopping IV insulin to prevent rebound hyperglycemia and recurrent ketoacidosis 24

Common Pitfalls to Avoid

The American Diabetes Association advises against discontinuing IV insulin when glucose normalizes, as ketoacidosis takes longer to resolve than hyperglycemia, and premature insulin cessation can cause recurrence 24
Bicarbonate therapy should not be used unless pH <6.9, as it provides no benefit in DKA resolution, according to the American Diabetes Association 24

Subsequent Management After Acidosis Resolution

Once acidosis resolves, metformin can be initiated while continuing subcutaneous insulin therapy, as recommended by the American Diabetes Association 23, 25
The distinction between type 1 and type 2 diabetes may be unclear initially in youth with ketoacidosis, and therapy should be adjusted once metabolic compensation is established and islet autoantibody results become available, according to the American Diabetes Association 26, 27

Dextrose-Containing Fluids in Patients with Nausea, Vomiting, and Ketonuria

Pathophysiology and Carbohydrate Requirements

The American Diabetes Association recommends that adults require 150-200 grams of carbohydrate daily to reduce or prevent starvation ketosis, which persists even during acute illness with hyperglycemia 28, 29
Without carbohydrate intake, the liver continues producing ketones even with insulin administration, indicating that both insulin and glucose are needed to resolve ketonuria 28, 29
Insulin alone cannot clear ketones without adequate carbohydrate substrate, emphasizing the need for both in managing ketosis 28, 29

Clinical Application and Monitoring

When plasma glucose falls to 250 mg/dL during DKA treatment, adding 5-10% dextrose to IV fluids while continuing insulin infusion is crucial to prevent hypoglycemia and allow insulin to clear ketones 30, 31
The American Diabetes Association suggests that providing fluids without dextrose in a vomiting patient with ketonuria perpetuates ketone production, even with insulin administration 28, 29
Monitoring blood glucose regularly is essential as dextrose infusion can cause hyperglycemia with subsequent osmotic diuresis 32

Practical Algorithm for Dextrose Administration

The American College of Physicians and the American Diabetes Association imply that assessing glucose level and ketone status is the first step in dextrose administration, followed by adding dextrose when glucose falls during treatment 30, 31
Continuing insulin infusion at 0.05-0.1 U/kg/h despite dextrose addition is recommended, with close monitoring of glucose every 1-2 hours 30, 31, 33
Transitioning to oral carbohydrate-containing fluids once nausea resolves, with liquid carbohydrates preferred if solid food is not tolerated, is advised by the American Diabetes Association 28, 29

Diabetic Ketoacidosis Treatment Guidelines

Initial Assessment and Diagnosis

The American Diabetes Association recommends calculating anion gap using [Na+] - ([Cl-] + [HCO3-]), which should be >10-12 mEq/L in DKA, to confirm diagnosis 34
Classify severity to guide monitoring intensity: severe DKA is characterized by pH <7.00, bicarbonate <10 mEq/L, and stupor/coma, requiring intensive monitoring 34

Fluid Resuscitation Protocol

The American Diabetes Association recommends administering isotonic (0.9%) saline at 15-20 mL/kg/hour for the first hour, regardless of corrected sodium level, to address the typical 6-9 liter total body water deficit 34
Target total fluid replacement of approximately 1.5 times the 24-hour maintenance requirements over 24 hours, with close monitoring for fluid overload in patients with cardiac or renal compromise 34

Potassium Replacement Strategy

DKA causes total body potassium depletion of 3-5 mEq/kg despite normal or elevated initial serum levels, and insulin therapy drives potassium intracellularly, causing rapid decline 34
The American Diabetes Association recommends a potassium replacement algorithm, including adding 20-30 mEq/L potassium to IV fluids (using 2/3 KCl and 1/3 KPO4) if K+ is 3.3-5.5 mEq/L 34

Special Considerations and Pitfalls

The American Diabetes Association recommends including phosphate replacement as 1/3 of potassium replacement (KPO4) to prevent severe hypophosphatemia 34

Diagnostic Criteria and Management of Diabetic Ketoacidosis (DKA)

Essential Laboratory Workup and Diagnostic Considerations

The American Diabetes Association recommends a complete blood count with differential, urinalysis, serum osmolality, and HbA1c to distinguish acute versus chronic poor control in patients with suspected DKA 35
The American Diabetes Association suggests measuring blood β-hydroxybutyrate, which is the gold standard for ketone assessment, and obtaining bacterial cultures if infection is suspected in patients with DKA 35
The American Diabetes Association recommends considering toxic ingestions, such as salicylate, methanol, or ethylene glycol, and measuring blood lactate to distinguish lactic acidosis from DKA 35
The American Diabetes Association suggests considering alcoholic ketoacidosis, clinical history, and glucose levels to differentiate it from DKA 35
The American Diabetes Association recommends considering starvation ketosis, bicarbonate levels, and chronic renal failure to differentiate them from DKA 35

Management of Diabetic Ketoacidosis – Evidence‑Based Recommendations

Fluid Resuscitation

Initiate aggressive isotonic saline (0.9 % NaCl) at 15–20 mL kg⁻¹ h⁻¹ during the first hour to restore circulatory volume and tissue perfusion. 36
The total body water deficit in typical DKA is ≈ 6–9 L; replacement should be planned to correct this deficit over the first 24 h. 36
Monitor closely for fluid overload in patients with underlying renal or cardiac dysfunction, adjusting the infusion rate as needed. 36

Insulin Therapy

For critically ill patients with altered mental status, continuous intravenous regular insulin infusion is the standard of care. [36][37]

Electrolyte Management

Hypokalemia occurs in roughly 50 % of patients during DKA treatment; severe hypokalemia (< 2.5 mEq L⁻¹) is linked to higher in‑hospital mortality. 36

Bicarbonate Use

Bicarbonate therapy is not recommended for routine DKA management and provides no benefit in acidosis resolution time or hospital length of stay; it should be reserved only for pH < 6.9. 37

Transition to Subcutaneous Insulin

Administer basal subcutaneous insulin 2–4 h before stopping the IV infusion to prevent rebound hyperglycemia and recurrence of ketoacidosis. 37
Estimate the required basal dose by averaging the IV insulin rate over the preceding 12 h (e.g., an average of 1.5 U kg⁻¹ h⁻¹ translates to ≈ 36 U per 24 h). 36
Ensure the patient is stable before transition: glucose values stable for ≥ 4–6 h, normal anion gap, resolved acidosis, hemodynamic stability, and a defined nutrition plan. 36

Discharge Planning

Identify the outpatient diabetes care provider before discharge. 37
Provide education on recognition, prevention, and management of DKA, as well as on hypoglycemia and hyperglycemia. 37
Verify that all new or adjusted medication prescriptions are filled and reviewed with the patient and family prior to discharge. 37
Arrange a follow‑up outpatient appointment before discharge to improve post‑hospital compliance. 37

Management of Diabetic Ketoacidosis in Adults (Cited Guidelines)

Initial Resuscitation and Fluid Management

Insulin Therapy

Transition to Subcutaneous Insulin

Bicarbonate Use

Alternative Regimens for Mild‑to‑Moderate DKA

Discharge Planning

Management of Euglycemic Diabetic Ketoacidosis: Fluid, Electrolyte, and Insulin Protocols

Fluid Resuscitation

Administer isotonic saline (0.9 % NaCl) at 15–20 mL/kg per hour for the first hour to restore circulatory volume; replace the typical total body water deficit of 6–9 L over the subsequent 24 hours, while closely monitoring for fluid overload in patients with renal or cardiac compromise. 40

Potassium Management

Serum potassium must be checked before insulin:
- K⁺ < 3.3 mmol/L – delay insulin and give aggressive potassium replacement to prevent fatal arrhythmias.
- K⁺ 3.3–5.5 mmol/L – add 20–30 mEq/L potassium to IV fluids, using a mixture of ≈ 2/3 potassium chloride and 1/3 potassium phosphate.
- K⁺ > 5.5 mmol/L – hold potassium supplementation and re‑measure frequently. 40

Insulin Therapy

Initiate a continuous IV regular insulin infusion at 0.1 units/kg/hour (no initial bolus) once potassium is ≥3.3 mmol/L.
If blood glucose does not fall by ≥50 mg/dL in the first hour, double the insulin rate hourly until a steady decline of 50–75 mg/dL per hour is achieved. 40

Monitoring for Cerebral Edema

Avoid overly aggressive fluid resuscitation and continuously assess mental status to detect early signs of cerebral edema, a rare but serious complication of rapid volume replacement. 40

Management of Severe Diabetic Ketoacidosis

Diagnostic Criteria

Blood glucose levels above 250 mg/dL are used as the diagnostic threshold for diabetic ketoacidosis (DKA) 41.

Mixed Metabolic‑Respiratory Acidosis

In DKA, low bicarbonate (≈12 mEq/L) and a pH around 7.00 indicate primary metabolic acidosis caused by accumulation of keto‑acids 42.
An arterial pCO₂ of ≈54 mm Hg (above the normal 34‑46 mm Hg) reflects a concurrent respiratory acidosis, signifying inadequate respiratory compensation [43][42].
The presence of an elevated pCO₂ in this setting suggests impending respiratory failure or respiratory‑muscle fatigue [42][44].

Neurologic Effects

Severe acidemia (pH ≈ 7.00) directly depresses central‑nervous‑system function, contributing to altered mental status 42.
Hyperosmolality generated by marked hyperglycemia (effective osmolality = 2 × [Na] + [glucose]/18) further impairs cerebral function 41.
Patients with DKA are at risk for cerebral edema during treatment, warranting close neurologic monitoring and imaging when indicated 41.

Airway and Respiratory Support

Endotracheal intubation is recommended for patients with a Glasgow Coma Scale < 8, a pH < 7.15 combined with respiratory acidosis, or severe respiratory distress that compromises airway protection 44.

Fluid Resuscitation

Initiate aggressive isotonic saline (0.9 % NaCl) at 15–20 mL kg⁻¹ hour⁻¹ during the first hour of therapy 41.
The estimated total body water deficit (≈ 6–9 L) should be replaced over the first 24 hours 41.
Continuous monitoring for fluid overload and signs of cerebral edema is essential, especially in patients with altered consciousness 41.

Insulin Therapy

Begin continuous intravenous regular insulin at 0.1 U kg⁻¹ hour⁻¹ without an initial bolus once serum potassium is ≥ 3.3 mEq/L 41.
When plasma glucose falls to 200–250 mg/dL, add 5–10 % dextrose to the intravenous fluids while maintaining the insulin infusion to ensure ongoing ketone clearance 41.

Potassium Management

If serum potassium is between 3.3–5.5 mEq/L, supplement the IV fluids with 20–30 mEq L⁻¹ of potassium (approximately two‑thirds potassium chloride and one‑third potassium phosphate) 41.

Ongoing Monitoring

Check venous pH, bicarbonate, glucose, electrolytes (Na⁺, K⁺, Cl⁻), BUN, creatinine, and the anion gap every 2–4 hours to track resolution of acidosis.
Measure β‑hydroxybutyrate levels preferentially over urine ketones for more accurate assessment of ketone clearance.

Cerebral Edema Surveillance

Maintain vigilant observation for signs of cerebral edema throughout fluid resuscitation, as rapid volume shifts increase this risk 41.

Key Pitfalls (Evidence‑Based Recommendations)

Do not discontinue IV insulin until ketoacidosis has resolved, even after plasma glucose normalizes 41.
Avoid subcutaneous insulin administration in unconscious or critically ill patients 41.
Do not withhold aggressive isotonic fluid replacement in DKA; adequate hydration is a cornerstone of therapy 41.

All statements are supported by the cited references.

Serum β‑Hydroxybutyrate in Diabetic Ketoacidosis (DKA) Diagnosis

Reference Values for Ketone Measurements

Normal fasting ketone concentrations are < 0.5 mmol/L. This threshold defines a non‑ketotic state and is used to interpret β‑hydroxybutyrate results. 45

Diagnostic Role of β‑Hydroxybutyrate

β‑OHB is the predominant ketone body in DKA and the strongest acid; nitroprusside‑based tests (urine dipsticks and some serum assays) detect only acetoacetate and acetone, thereby missing the majority of ketone burden. 45
Direct blood β‑OHB measurement should be employed for both diagnosis and ongoing monitoring of DKA, because it captures the primary ketone body and reflects treatment response accurately. [46][45]
Hyperglycemia component of DKA: a blood glucose level > 250 mg/dL is required when combined with ketonemia and acidosis. 46
Metabolic acidosis component of DKA: a venous pH < 7.3 together with a serum bicarbonate < 18 mEq/L defines the acid‑base disturbance. 46

Monitoring During Treatment

β‑OHB clearance lags behind glucose normalization; therefore, β‑OHB should be re‑checked every 2–4 hours even after blood glucose has returned to target levels. 45
Resolution of DKA includes normalization of β‑OHB to < 0.5 mmol/L before therapy is considered complete. 45

Common Pitfalls

Urine ketone testing is insufficient for DKA diagnosis or monitoring because it lacks specificity and does not detect β‑OHB, leading to missed or delayed recognition of ongoing ketoacidosis. 45

Management of Mild Diabetic Ketoacidosis (ADA Guidelines)

Insulin Therapy

Fluid Resuscitation

Potassium Management

Glucose Management During Treatment

Bicarbonate Therapy

Criteria for DKA Resolution

Transition to Subcutaneous Insulin Regimen

Monitoring & Pitfalls

Arteriovenous pH Relationship and Its Use in Diabetes‑Related Acid‑Base Monitoring

Physiologic Basis

Under normal hemodynamic conditions, venous blood pH is on average 0.03 units lower than arterial pH, and venous PCO₂ is approximately 5.7 mm Hg higher – a stable arteriovenous gradient that forms the basis for clinical correction. 50

Standard Correction

In hemodynamically stable patients, adding 0.03 to a measured venous pH provides an accurate estimate of the corresponding arterial pH (e.g., venous pH 7.33 → arterial pH ≈ 7.36). 50

Diabetes‑Ketoacidosis (DKA) Monitoring

The American Diabetes Association (ADA) recommends using venous pH alone for DKA monitoring because the 0.03‑unit arteriovenous difference is reliably predictable in this population; arterial blood gases are not required for routine assessment. 50
For DKA resolution, a venous pH > 7.3 is the accepted criterion, eliminating the need for arterial sampling. This guideline is supported by both ADA statements and the cited Diabetes Care source. [51][50]
Venous pH measurement is sufficient to track the decline of acidosis during DKA treatment, providing a practical alternative to repeated arterial blood‑gas analysis. 50

Epidemiology and Management of Euglycemic Diabetic Ketoacidosis

Epidemiology & Typical Triggers

Euglycemic DKA is increasingly observed in patients using sodium‑glucose cotransporter‑2 (SGLT2) inhibitors, in pregnancy, during periods of starvation or reduced oral intake, and after recent insulin administration. 52

Immediate Therapeutic Recommendations

SGLT2‑inhibitor–associated euglycemic DKA: The offending SGLT2 inhibitor should be stopped immediately and should not be restarted until the patient has been metabolically stable for 3–4 days. 52
Pregnancy‑related euglycemic DKA: Pregnant individuals are prone to presenting with euglycemic DKA, often accompanied by mixed acid‑base disturbances; clinicians should maintain a high index of suspicion. 52
Starvation‑related euglycemic DKA: Acute illness with nausea or vomiting leading to reduced oral intake or fasting is a common precipitant of euglycemic DKA. 52

Management of Mild Ketonemia with Moderate Hyperglycemia

Immediate Treatment

Administer a rapid‑acting insulin correction dose of 2–4 units subcutaneously (or calculate using the insulin‑sensitivity factor) when blood glucose is ≈13.8 mmol/L (≈248 mg/dL) to suppress ketone production. 53
For patients on a basal‑bolus regimen, give the correction dose in addition to the scheduled basal insulin and never omit the basal dose, as basal insulin provides continuous inhibition of lipolysis and ketogenesis. 53
Ingest 200–300 mL of water or sugar‑free fluid immediately, then continue 100–150 mL every 30 minutes for the next 2–3 hours to restore circulating volume and promote renal clearance of ketones. 53
If the individual has been fasting, vomiting, or otherwise has reduced oral intake, consume 15–30 g of carbohydrate (e.g., juice, crackers, glucose tablets) together with the insulin dose to prevent starvation‑induced ketosis. 53
Adults generally require 150–200 g of carbohydrate per day to suppress hepatic ketone production; insulin alone cannot fully clear ketones without adequate carbohydrate intake. 53

Monitoring and Re‑assessment

Re‑measure blood glucose and β‑hydroxybutyrate 1–2 hours after the initial intervention; glucose should decline by roughly 50–75 mg/dL per hour and ketone levels should begin to fall. 53
If glucose falls below 200 mg/dL (11.1 mmol/L) while ketones remain elevated, add carbohydrate‑containing fluids (e.g., diluted juice or sports drink) while continuing insulin to avoid hypoglycemia and facilitate ketone clearance. 53

Escalation Criteria (When to Seek Emergency Care)

Ketone concentration rises above 1.5 mmol/L despite treatment. 53
Blood glucose exceeds 300 mg/dL (16.7 mmol/L) or fails to decline with therapy. 53
Development of nausea, vomiting, abdominal pain, or altered mental status—signs of progressing diabetic ketoacidosis. 53
Inability to tolerate oral fluids because of persistent vomiting. 53

Pathophysiological Rationale

Rapid‑acting insulin suppresses lipolysis and hepatic ketogenesis, directly halting further ketone production. 53
Aggressive hydration restores renal perfusion, enabling the kidneys to excrete excess glucose and ketones and preventing worsening osmotic diuresis. 53
Appropriate carbohydrate intake provides metabolic substrate that shifts oxidation away from fatty acids toward glucose, reducing ketone generation. 53

Common Pitfalls to Avoid

Skipping basal insulin even when oral intake is limited; basal insulin is essential for suppressing hepatic glucose output and ketogenesis independent of meals. 53
Administering a rapid‑acting insulin correction at bedtime without planning a glucose/ketone recheck within 1–2 hours, which raises the risk of nocturnal hypoglycemia. 53

Special Considerations

In situations of illness, fasting, or vomiting, the combination of starvation ketosis and hyperglycemia creates a “double hit” that accelerates ketone production; therefore, aggressive carbohydrate and fluid replacement are especially critical. 53

Resolution Targets

Blood glucose should return to the individual’s usual target range (approximately 80–180 mg/dL or 4.4–10 mmol/L). 53
After ketone clearance, resume the regular diabetes regimen (basal insulin, oral agents, etc.) and arrange follow‑up within 24–48 hours to identify and address the precipitating factor. 53

Initial Fluid Resuscitation Prioritization and Common Precipitating Causes in Uncontrolled Diabetes with Repeated Vomiting

Fluid Resuscitation Prioritization

The American Diabetes Association (based on Diabetes Care 2015) recommends that the first‑hour aggressive isotonic saline infusion (0.9 % NaCl at 15–20 mL/kg) is critical and should take priority over the initiation of insulin in patients with suspected diabetic ketoacidosis. 54

Common Precipitating Causes of DKA

Myocardial infarction is identified as one of the frequent triggers that must be concurrently diagnosed and treated in patients presenting with uncontrolled diabetes and repeated vomiting. 54
Insulin omission or inadequate insulin dosing is also a common precipitating factor for diabetic ketoacidosis and should be addressed promptly alongside other supportive measures. 54